Infectious Diseases (except HIV/AIDS)

  1. BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

    1. Annika Rössler
    2. Antonia Netzl
    3. Ludwig Knabl
    4. Helena Schäfer
    5. Samuel H. Wilks
    6. David Bante
    7. Barbara Falkensammer
    8. Wegene Borena
    9. Dorothee von Laer
    10. Derek J. Smith
    11. Janine Kimpel

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  2. Influencing factors of anti‐SARS‐CoV‐2‐spike‐IgG antibody titers in healthcare workers: A cross‐section study

    1. Julia Reusch
    2. Isabell Wagenhäuser
    3. Alexander Gabel
    4. Annika Eggestein
    5. Anna Höhn
    6. Thiên‐Trí Lâm
    7. Anna Frey
    8. Alexandra Schubert‐Unkmeir
    9. Lars Dölken
    10. Stefan Frantz
    11. Oliver Kurzai
    12. Ulrich Vogel
    13. Manuel Krone
    14. Nils Petri

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants

    1. Haissam Abou-Saleh
    2. Bushra Y. Abo-Halawa
    3. Salma Younes
    4. Nadin Younes
    5. Duaa W. Al-Sadeq
    6. Farah M. Shurrab
    7. Na Liu
    8. Hamda Qotba
    9. Nader Al-Dewik
    10. Ahmad H. Ismail
    11. Hadi M. Yassine
    12. Laith J. Abu-Raddad
    13. Gheyath K. Nasrallah

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia

    1. Rui Li
    2. Hanting Liu
    3. Christopher K Fairley
    4. Jason J Ong
    5. Yuming Guo
    6. Pengyi Lu
    7. Zhuoru Zou
    8. Li Xie
    9. Guihua Zhuang
    10. Yan Li
    11. Mingwang Shen
    12. Lei Zhang

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Orphanhood and Caregiver Loss Among Children Based on New Global Excess COVID-19 Death Estimates

    1. Susan Hillis
    2. Joel-Pascal Ntwali N’konzi
    3. William Msemburi
    4. Lucie Cluver
    5. Andrés Villaveces
    6. Seth Flaxman
    7. H. Juliette T. Unwin

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

    1. Natalia Martin Orozco
    2. Noah Vale
    3. Alan Mihic
    4. Talya Amor
    5. Lawrence Reiter
    6. Yuko Arita
    7. Reuben Samson
    8. Queenie Hu
    9. Anne-Claude Gingras
    10. Brad Sorenson
    11. Eric G. Marcusson
    12. Piyush Patel

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. Performance of Existing and Novel Symptom- and Antigen Testing–Based COVID-19 Case Definitions in a Community Setting

    1. Scott Lee
    2. Olivia Almendares
    3. Jessica Prince-Guerra
    4. Mark Anderson
    5. Charles M Heilig
    6. Jacqueline E Tate
    7. Hannah L Kirking

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. Routine saliva testing for SARS-CoV-2 in children: Methods for partnering with community childcare centers

    1. Erica J. Rayack
    2. Hibah Mahwish Askari
    3. Elissa Zirinsky
    4. Sarah Lapidus
    5. Hassan Sheikha
    6. Chikondi Peno
    7. Yasaman Kazemi
    8. Devyn Yolda-Carr
    9. Chen Liu
    10. Nathan D. Grubaugh
    11. Albert I. Ko
    12. Anne L. Wyllie
    13. Erica S. Spatz
    14. Carlos R. Oliveira
    15. Amy K. Bei

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern

    1. Fulvia Mazzaferri
    2. Massimo Mirandola
    3. Alessia Savoldi
    4. Pasquale De Nardo
    5. Matteo Morra
    6. Maela Tebon
    7. Maddalena Armellini
    8. Giulia De Luca
    9. Lucrezia Calandrino
    10. Lolita Sasset
    11. Denise D'Elia
    12. Emanuela Sozio
    13. Elisa Danese
    14. Davide Gibellini
    15. Isabella Monne
    16. Giovanna Scroccaro
    17. Nicola Magrini
    18. Annamaria Cattelan
    19. Carlo Tascini
    20. MANTICO Working Group
    21. Evelina Tacconelli

    • Curated by eLife

      Evaluation Summary:

      This paper will be of broad interest to clinicians and scientists in the area, providing clinical trial data on how the efficacy of monoclonal antibodies targeting SARS-CoV-2 varies according to the variant of concern. The clinical outcome data were consistent with previously reported in vitro data, which are being used to inform the clinical use of monoclonal antibodies. However, as the trial was stopped early, conclusions regarding the efficacy and safety of the individual monoclonal antibodies are limited.

      (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. Reviewer #3 agreed to share their name with the authors.)

    Reviewed by eLife, ScreenIT

    5 evaluationsAppears in 2 listsLatest version Latest activity

  10. Clinical and Virological Features of Patients Hospitalized with Different Types of COVID-19 Vaccination in Mexico City

    1. Alejandra Hernández-Terán
    2. Pamela Garcíadiego-Fossas
    3. Marco Villanueva-Reza
    4. Celia Boukadida
    5. Blanca Taboada
    6. Eduardo Porras
    7. Victor Ahumada-Topete
    8. Kathia Elizabeth Tapia-Diaz
    9. Margarita Matías-Florentino
    10. Marissa Pérez-García
    11. Santiago Ávila-Ríos
    12. Fidencio Mejía-Nepomuceno
    13. Ricardo Serna-Muñoz
    14. Fortunato Juárez-Hernández
    15. María Eugenia Jiménez-Corona
    16. Eduardo Becerril-Vargas
    17. Omar Barreto
    18. Jose Arturo Martínez-Orozco
    19. Rogelio Pérez-Padilla
    20. Carlos F. Arias
    21. Joel Armando Vázquez-Pérez

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 162 of 716 Next